Evaluation of Sumatriptan‐Naproxen in the Treatment of Acute Migraine: A Placebo‐Controlled, Double‐Blind, Cross‐Over Study Assessing Cognitive Function. Issue 4 (13th February 2013)

• Record Type: Journal Article
• Authors: Edwards, Keith R.; Rosenthal, Barbara L.; Farmer, Kathleen U.; Cady, Roger K.; Browning, Rebecca
• Is Part Of: Headache. Volume 53:Issue 4(2013)
• Page Start: 656
• Page End: 664
• Publication Date: 2013-02-13
• Subjects: Headache -- Periodicals; Headache -- Periodicals; 616.8491
• DOI: 10.1111/head.12052
• Languages: English
• ISSNs: 0017-8748

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="head12052-sec-0001" sec-type="section"> <title>Objective</title> <p>To assess the cognitive effects of acute migraine and the subsequent impact of acute treatment in a controlled setting.</p> </sec> <sec id="head12052-sec-0002" sec-type="section"> <title>Background</title> <p>Cognitive dysfunction may be an associated symptom in patients with migraine with or without aura. The loss of cognitive efficiency in migraine may be disabling and is often under recognized.</p> </sec> <sec id="head12052-sec-0003" sec-type="section"> <title>Methods</title> <p>Thirty migraine patients were prospectively studied for cognitive function before and then at the beginning of a migraine using a computerized cognitive battery (Mental Efficacy Workload Test). Each patient then was treated for 2 headaches in a cross‐over manner with sumatriptan‐naproxen (Treximet®) or placebo in a double‐blind, placebo‐controlled fashion with cognitive testing repeated at 1 and 2 hours post‐dose.</p> </sec> <sec id="head12052-sec-0004" sec-type="section"> <title>Results</title> <p>Twenty‐five of the 30 screened migraine subjects completed study‐specific procedures and were included in the data analyses. There were no significant side effects from Treximet or placebo and no serious adverse events. At the onset of headache, there was a statistically significant decline in overall cognitive efficiency compared with the baseline cognitive testing (migraine‐free) for all subjects (<italic>P</italic> = .001 paired samples <italic>t</italic>‐test). For subjects taking Treximet compared with taking placebo, there was a statistically significant return to cognitive efficiency by measures of immediate and sustained attention, visual‐spatial awareness, mental flexibility, and reaction time between 1 hour and 2 hours (<italic>P</italic> = .05). There was no statistical significance between patients taking Treximet or placebo in measures of complex reasoning or fine motor coordination. Subanalysis showed a correlation between headache severity and Performance Index in the Treximet group but not in the placebo group (∼Fig. <xref ref-type="link" rid="head12052-fig-0006">6</xref>).</p> </sec> <sec id="head12052-sec-0005" sec-type="section"> <title>Conclusions</title> <p>There is a significant decline in global cognitive efficiency at the onset of an attack of migraine. The use of Treximet allows a significantly faster recovery time in some measures of cognitive efficiency compared with placebo. Decline of cognitive efficiency may be independent of headache severity.</p> </sec> </abstract>